GLP1_NEW
GZR18 (bofanglutide) 4.8 mg injection once weekly
GZR18_SC_4p8MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -7.29 (-23.64 to 9.41) | 0.64 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -14.20 (-26.04 to -1.95) | 0.78 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 19.93 (1.14 to 431) | 0.64 |